Overview

This is a Phase 1 Study to Compare Pharmacokinetics of BDA/MDI Compared to Pulmicort Respules in Children With Asthma Aged 4 to 8 Years

Status:
Completed

Trial end date:
2021-07-08

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetics of budesonide delivered by a metered dose inhaler containing budesonide / albuterol (BDA MDI) compared to budesonide delivered by Pulmicort Respules in children with asthma aged 4 to 8 Years.

Phase:

Phase 1

Details

Lead Sponsor:

Bond Avillion 2 Development LP

Treatments:

Budesonide